Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2014

Open Access 01-12-2014 | Poster presentation

PB.28. Determination of recall rates for assessment in women undergoing annual surveillance breast MRI: is a rate <10% achievable?

Authors: N Healy, S Cosgrove, P Wen, T Kwa, F O'Driscoll, G Offiah, Y Roden, S Sebaoui, K Wolohan, S O'Keeffe

Published in: Breast Cancer Research | Special Issue 1/2014

Login to get access

Excerpt

High recall rates from surveillance breast MRI are associated with patient anxiety and increased workload. NHSBSP guidelines recommend a maximum of a 10% recall rate with an expected rate of <7% in high-risk women undergoing surveillance with breast MRI. Our aims were to review surveillance breast MRIs performed at our institution from 2009 to 2013 to determine the recall rate and cancer detection rates. …
Metadata
Title
PB.28. Determination of recall rates for assessment in women undergoing annual surveillance breast MRI: is a rate <10% achievable?
Authors
N Healy
S Cosgrove
P Wen
T Kwa
F O'Driscoll
G Offiah
Y Roden
S Sebaoui
K Wolohan
S O'Keeffe
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2014
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3720

Other articles of this Special Issue 1/2014

Breast Cancer Research 1/2014 Go to the issue

Poster presentation

PB.27. Breast screening with MRI in high-risk women

Poster presentation

PB.23. Breast density in previous screening mammograms of women with and without breast cancer

Poster presentation

PB.44. Do qualitative patterns of stiffness help differentiate benign from malignant breast masses of similar stiffness during shear wave elastography?

Poster presentation

PB.31. Occult breast carcinoma: an experience at a single unit

Poster presentation

PB.36. Imaging in gynaecomastia: audit of referral and imaging practise to establish referral guidelines

Oral presentation

Efficacy of second-time vacuum-assisted breast excision in the management of screen-detected high-risk breast lesions
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits